A5071261900- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Kruppel-like factors research
- Protein Degradation and Inhibitors
- Advanced Breast Cancer Therapies
- Eosinophilic Disorders and Syndromes
- Nutrition and Health in Aging
- Peptidase Inhibition and Analysis
- Frailty in Older Adults
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Glycosylation and Glycoproteins Research
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
Central University Hospital of Asturias
2015-2024
Instituto de Investigación Sanitaria del Principado de Asturias
2017-2023
Instituto de Investigación Biosanitaria de Granada
2020
Universidad de Oviedo
2018
The inclusion of monoclonal antibodies targeting immune checkpoints such PD-1/PD-L1 or CTLA-4 has revolutionized the landscape anti-cancer therapy. However, PD-1 and blockade failed to achieve clinical benefit in CLL, thus attention been focused on emerging this malignancy. LAG-3 is an checkpoint receptor that negatively regulates T cell-mediated responses by inducing hyporesponsive state, promoting tumor escape. Patients with chronic lymphocytic leukemia (CLL) develop a profound suppression...
The immune system may mediate anti-tumor responses in chronic lymphocytic leukemia (CLL) which affect disease progression and survival. In this study, we analyzed the characteristics of 99 consecutive previously diagnosed CLL patients 50 healthy controls. distribution lymphocyte subsets at diagnosis was retrospectively analyzed. Compared with controls, showed an expansion NK CD8 T cells diagnosis. relative number associated time to treatment, suggesting that modify progression. again when...
Lenalidomide is an immunomodulatory drug with therapeutic activity in chronic lymphocytic leukemia (CLL). However, it has pleiotropic effects, and the mechanism of action responsible for its not been well defined yet. Herein, we show that lenalidomide treatment does have effect on proliferation cells, but increases B cells from healthy donors. did exert a direct apoptosis obtained CLL patients, although indirectly induced their through activation nonmalignant immune cells. Thus, markedly...
Mutations in genes of the RAS-BRAF-MAPK-ERK pathway have not been fully explored patients with chronic lymphocytic leukemia. We, therefore, analyzed clinical and biological characteristics leukemia mutations this investigated
Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as powerful tool to reinvigorate antitumor responses. Herein, we analyzed the role of novel inhibitory BTLA its ligand, HVEM, in regulation leukemic natural killer (NK) cells CLL. Flow cytometry analyses showed that expression upregulated on NK from patients with CLL,...
One of the cardinal features chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function markedly impaired in CLL patients, who show significant dysregulation expression activating and inhibitory receptors. Here, we analyzed role novel receptor Ig-like transcript 2 (ILT2, also termed LIR-1, LILRB1) regulation cells CLL. Our results that ILT2 was significantly decreased on leukemic increased particularly those advanced disease bad prognostic...
IntroductionThe GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies higher risk of treatment-related toxicity. Our objective this study was to determine the weights for each dimension and cut-off point reliably predict treatment tolerability population, estimated by weighted receiver operating characteristic (ROC) analysis quantified area under curve (AUC).Material MethodsThe RETROGAH...
Plasmablastic lymphoma (PBL) is a rare sub-type of non-Hodgkin's (NHL) strongly associated with human immunodeficiency virus (HIV) infection, accounting for 2% all AIDS-related lymphoma...
Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management outcome of CLL receiving ibrutinib routine practice Spain.Observational, retrospective, multicenter who started single-agent as first-line treatment at first second relapse between January 2016 2019.A total 269 were...
This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at time asymptomatic biochemical relapse. One hundred were randomized to receive either (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups well balanced for disease prognostic features. Zoledronic did show an antitumor according changes in M-component. However, there fewer symptomatic progressions experimental group than (34 versus 41, respectively; P=0.05)...
Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone regimen consisting of one cycle twice weekly for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, 32), (90 1 4) prednisone. The following cycles included once weekly. Patients who transplant candidates proceeded to stem cell collection after four the was performed six cycles. not transplantation received...
Abstract Patients with chronic lymphocytic leukemia (CLL) progressively develop marked immunosuppression, dampening innate and adaptive-driven antitumor responses. However, the underlying mechanisms promoting immune exhaustion are largely unknown. Herein, we provide new insights into role of BTLA/HVEM axis defects in T cell-mediated responses against leukemic cells. Increased expression BTLA, an inhibitory checkpoint, was detected on surface CD4 + CD8 lymphocytes patients CLL. Moreover, high...
Chronic lymphocytic leukemia (CLL) is associated with a profound dysregulation of the immune system. Loss T cell function frequently caused in cancer by sustained signaling inhibitory receptors. Here, we analyzed role novel receptor Ig-like transcript 2 (ILT2) pathogenesis CLL. We observed that ILT2 expression was markedly reduced on leukemic cells, whereas it increased CD8 and CD4 cells from CLL patients, particularly those patients harboring chromosome 11q deletion, which includes ATM...